“Project Management for Biotech: A Practical Guide”

Project management for biotech is the discipline of keeping an evidence-producing machine on a fixed calendar while the science stays genuinely uncertain. A 38-person oncology company promises investors a Phase II readout in 14 months. Its CDMO has just failed a second engineering batch, the CMC lead left in March, and the trial master file is 71% complete three weeks before a sponsor audit. None of those is a science problem. All three are schedule problems, and each will be reported to the board as a science problem unless the plan can prove otherwise.

The uncertainty is not a planning failure to be smoothed away. The documents, gates, and regulatory clocks are what make the plan plannable in the first place. Generic advice about standups and sprints does not survive contact with a quality assurance review, because the artifacts that end a phase are not deliverables in the ordinary sense. They are legal evidence.

This guide covers the regulatory scaffolding that dictates the schedule, the phase model most programs actually follow, tech transfer, submission waves, the arithmetic of runway and enrollment, and where the honest boundary sits between a planning tool and a validated system.

What does project management for biotech actually deliver?

It delivers a defensible sequence of evidence. The output of a biotech project is not a feature or a shipment; it is an argument, assembled from data and documents, that a regulator, an auditor, or an investor can test. Three sentences cover the discipline: you build the schedule backwards from submission gates, size the risky parts with runway and enrollment arithmetic, and keep every change traceable to an approving role.

Two dependency types then coexist on the same board. Scientific dependencies (“we cannot start the tox study until the candidate is chosen”) are probabilistic and often wrong in helpful ways. Compliance dependencies (“we cannot dose the first patient until the CTA is approved and the site is activated”) are deterministic and rarely early. Good plans keep them visually separate, because they fail for different reasons and get fixed by different people.

There is a third property that catches experienced managers: the plan itself is an auditable object. If you move a gate, someone must be able to reconstruct who approved the change, on what evidence, and under which change control. A Gantt chart that only shows new dates is not a record. It is a screenshot.

Which regulations shape the plan before the first task is written?

Four families of rules touch almost every program: GLP for preclinical safety, GCP for human trials, GMP for manufacturing, and GDP for distribution. Each imposes a document artifact that becomes a hard predecessor in the schedule.

Two of these deserve emphasis in 2026. ICH E6(R3) reframed GCP around quality by design: the sponsor must define what matters to trial quality and focus oversight there, rather than applying identical monitoring intensity everywhere. In planning terms, a risk assessment is now a deliverable with a date, not a paragraph in a protocol. Separately, the EU Clinical Trials Regulation transition ended on 31 January 2025, so EU trials now run through CTIS with a single application and a defined review clock. Programs that still plan European startup on the old national timelines are planning against a process that no longer exists.

What does the clinical phase model look like inside a plan?

The familiar Phase I to III sequence is real, but the durations that matter are the ones between gates, not the phase labels. Use the table below as a sizing prior, then replace it with your own site data.

Three planning rules follow. First, the regulatory review clock is the only part of the schedule you cannot compress with resources, so protect it and never model it optimistically. Second, site activation is usually longer than the clinical team expects: contracts, ethics submission, pharmacy setup, and site training routinely consume three to five months per country wave. Third, the CMC package is the most common silent predecessor. A trial that is ready to enroll but has no released drug product is not ready.

How do you run tech transfer without stopping the plant?

Treat it as a gated transfer project with a defined knowledge package, at least one engineering run, and a formal performance qualification. ICH Q10 and Q11 describe the quality system expectations; ICH Q12 governs the post-approval change logic that determines how much of the transfer must be filed.

The knowledge package is where transfers fail. It should contain the process description with critical process parameters and critical quality attributes, analytical methods with transfer protocols, equipment and facility gap assessment, deviation history from the sending site, and the scale-dependent assumptions that were never written down because everyone knew them. That last item is the one that costs a quarter.

The gate sequence that works: method transfer and qualification, engineering or technical run, process performance qualification with three consecutive successful batches, then stability initiation, then the regulatory action. Skipping the engineering run to save six weeks is the most expensive six weeks in the program, because a failed PPQ batch triggers an investigation, a deviation, a CAPA, and usually a delay measured in months.

How do you plan a regulatory submission wave?

Backwards from the agency’s clock, with the module owners named. A marketing application is not one document but five modules, and the CMC module alone can run to thousands of pages that must reconcile with the batch records already executed.

Start with the submission date and subtract the agency’s validation and review periods, then subtract a two-week freeze for quality control and a further two weeks for the electronic publishing and validation pass. That publishing step fails more often than teams expect, on hyperlinks, bookmarks, and regional formatting, and it fails at the worst possible moment. The remaining window is the true authoring window, and it is usually 30% to 40% shorter than the plan assumed.

Two habits make waves survivable. First, assign a single accountable owner per module and a separate readiness tracker for each, because a module at 95% is not a module. Second, run a mock sequence of the publishing and validation steps at roughly the halfway point, using placeholder content. Teams that do this find the four broken cross-references while there is still time to fix them, rather than during the final week when the only remaining option is to delay the filing.

How do you keep a GxP project board audit-ready?

Add five fields to every task and never negotiate them away: GxP impact (yes, no, indirect), controlled document ID, accountable role rather than a person’s name, evidence link, and change control reference. With those fields, an auditor’s question (“show me how this decision was made”) becomes a filter, not an archaeology project.

Keep the system boundary explicit. A validated eQMS owns controlled documents and electronic signatures. A CTMS owns subject visit data. An eTMF owns the trial documentation index. The planning layer owns sequence, dependency, ownership, and the evidence that a gate was actually passed. When those boundaries blur, teams end up storing regulated records in a tool that was never validated for them.

How do you calculate runway against milestone need?

Divide cash by net burn, then compare that number to the months required to reach the next value-inflection gate, not the next task.

Worked example. A company holds $38.4 million after a Series B and burns $3.2 million net per month. Runway is 38.4 ÷ 3.2 = 12.0 months. The plan to the Phase II interim analysis needs 16 months, including a four-month CMC delay. The gap is 4 months, which at current burn is $12.8 million.

Funding the gap is one option. The cheaper option is usually scope: pausing a second indication saves $0.55 million per month for six months, worth $3.3 million, and deferring one Phase I site startup saves a further $0.9 million. That closes roughly a third of the gap without touching the critical path. The number that belongs on the board slide is not runway in months. It is runway minus months-to-gate, expressed in cash. “We are $12.8 million short of the readout” starts a different conversation than “we have 12 months of cash.”

How do you size enrollment and site activation?

Enrollment is a rate problem with three multipliers: number of active sites, patients per site per month, and screen failure rate.

Worked example. A Phase II trial needs 480 randomized patients. Planning assumes 18 sites, 0.85 patients per site per month, and a 28% screen failure rate, so 667 patients must be screened. Monthly enrollment is 18 × 0.85 = 15.3 patients. The enrollment period is 480 ÷ 15.3 = 31.4 months, plus 4 months of staggered site activation, giving 35.4 months to last-patient-in.

If the program can only afford 26 months to last-patient-in, required monthly enrollment is 480 ÷ 22 = 21.8 patients, which at 0.85 per site needs 25.7 sites, so 26 sites. That is eight additional sites, each with a three-to-four-month activation cost and a per-site startup budget that must appear in the same plan. This is why “add sites” is not a free schedule lever, and why the site count should be revisited monthly against actual screening data rather than at quarterly steering meetings.

How should CRO and vendor oversight be structured?

By risk, with a small number of leading indicators reviewed on a fixed cadence. Four are usually enough: site activation versus plan, screening-to-randomization conversion, query aging in the EDC, and trial master file completeness by site.

The failure mode in vendor oversight is measuring activity instead of evidence. Number of monitoring visits is activity. Percentage of critical source documents verified, and median days to resolve a critical query, are evidence. Under the risk-proportionate logic of E6(R3), you are expected to be able to explain why you monitored some sites more than others, so record that rationale when you make it, not when the inspector asks.

What trade-offs does biotech planning force?

Speed against evidence quality is the permanent one. Compressing a stability program, running a single engineering batch, or filing with a thinner CMC module all buy weeks now and sell months later. The honest move is to price the trade: state which gate slips if the shortcut fails, and get that accepted by the person who owns the budget.

Single source against dual source is the second. A second supplier for a critical raw material costs money and management attention, and it saves programs. The rule that works is to dual-source anything with a lead time longer than one quarter or a single qualified supplier.

In-house against outsourced is the third. Outsourcing buys capacity and expertise but adds a coordination surface that must itself be planned, with named owners and a transfer package. Teams routinely outsource the work and forget to plan the interface.

What mistakes show up most often?

• Planning to the label instead of the gate. “Phase II starts in Q3” is not a plan. “First patient in on 14 March, contingent on CTA approval by 2 February and drug product release by 28 February” is.
• Treating documentation as a deliverable that can trail. It cannot. The document is the gate.
• Letting the CMC workstream report separately. If manufacturing is not on the same board as clinical, the two will diverge quietly for a quarter.
• Confusing a milestone with a decision. A milestone is a date; a decision has an owner, criteria, and a recorded outcome.
• No change log on the plan itself. When the timeline moves eleven times, nobody can say which move was the one that mattered.

Where does Doitify fit in a biotech program?

Doitify is our product, so read this as disclosure rather than review. It handles the planning layer: programs, projects, tasks, owners, dependencies, Gantt and roadmap views, workload, and reporting across workstreams, with document attachments and an activity history that shows who changed what.

In a GxP context the useful pattern is to use Doitify for the gate plan and cross-functional dependencies, and keep controlled records where they belong: the eQMS for SOPs and CAPAs, the CTMS for subject data, the eTMF for trial documentation. Doitify is not a validated system for regulated records, and no planning tool should be described as one without a validation package covering intended use, installation and operational qualification, and Part 11 controls. The value is coordination: one board where clinical, CMC, regulatory, and quality see the same gate dates and the same blocking dependencies.

Conclusion

Biotech project management is not generic project management with more paperwork. It is planning against a compliance clock that does not negotiate, with a science clock that will move. The teams that do it well build the schedule backwards from gates, size it with runway and enrollment arithmetic, keep the plan auditable, and say plainly which trade-off they are accepting when they compress something.

Start with two artifacts this month: a gate list with named owners and evidence requirements, and a runway-to-gate calculation in cash rather than months. Everything else in the plan is detail that those two will organize.

If this post on project management for biotech was helpful, you might also enjoy Workplace Productivity Statistics for 2026 and How to Reduce Context Switching at Work (2026 Guide).